Epic Bio

This week we will attend the BMO 2024 Genetic Medicines Summit in New York City. Interested in learning more about our leading epigenetic editing platform? Reach out to set up a meeting at amber.salzman@epic-bio.com. BMO Capital Markets

Our platform includes some of the smallest Cas proteins known to work in human cells (half the size of Cas9!) — and today we’re proud to take a major step toward enabling other scientists to use them as well. Together with our founder Lei (Stanley) Qi, we are launching the first dCasMINI Guide Design Tool, to make designing guide RNA for dCasMINI as easy as it is for the first-generation Cas9 or Cas12a. The tool, which is freely accessible at https://lnkd.in/gz4jbvJ8, allows researchers to generate optimal gRNA sequences to activate or suppress more than 99% of human genes with just a single click. It also provides a comprehensive genome-wide assessment of off-target matches. To learn more about how the dCasMINI Guide Design Tool works, check out our recent updated preprint: https://lnkd.in/gzYz8bey Our hope is that this tool makes epigenetic modulation studies quicker and easier to perform, and expands access to dCasMINI for researchers across a wide variety of disciplines. #biotechnology #CRISPR #epigenetics #guidedesign

The future of CRISPR may not look like the CRISPR you’re familiar with, Epic scientific founder Lei (Stanley) Qi and Yitong Ma write in Nature Portfolio. Certain challenges continue to be issues for CRISPR medicines, including safety concerns, delivery challenges, and limited range of diseases that are conducive to gene editing. The next generation of #CRISPR, including #EpigeneticEditing, are paving the way to “addressing the nuanced and complex nature of many diseases, moving beyond the limitations of current CRISPR applications,” they write. Read the full article here: https://lnkd.in/dHGRZHWY

Great to see Epic featured in Labiotech.eu's top companies to watch in CRISPR’s next wave of therapeutics! Using modified CRISPR machinery, we’re able to dial up or down the expression of genes, without making any cuts to the DNA. And with our hypercompact CasMINI protein, we can fit our medicines within a single AAV vector. It’s a very exciting time to be writing the next chapter of #CRISPR! Read the article here: https://lnkd.in/eSD2AZF3

At #ASGCT24 we presented some exciting new data on our best-in-class epigenetic activators, showing that we could robustly and durably activate a target gene in vivo. If you missed our presentation, check out this interview with our Head of Technology Daniel Hart PHD, who spoke with CGTLive about the significance of the results and how they expand upon our leading platform for #EpigeneticEditing.

Today is #WorldFSHDDay. Over 1 million individuals globally suffer from FSHD often have facial muscle weakness and have difficulties in simple tasks, including smiling, lifting their arms, or walking. At #EpicBio, we work tirelessly towards finding a cure for #FSHD and bringing back their smiles! #epigeneticediting #CureFSHD

Epic scientific founder Lei (Stanley) Qi is one of the world’s leading #CRISPR experts. Recently he shared his thoughts on all things gene editing with Stanford University's Stanford Report — from the basics of CRISPR to its next-generation applications in #EpigeneticEditing.    In the article, Dr. Qi explains how the hypercompact CasMINI, which Epic Bio has an exclusive license to, can be paired with epigenetic editing approaches to potentially treat a vast range of diseases that aren’t amenable to today’s gene editing approaches.    Read the story here: https://lnkd.in/e733n2EG #biotechnology

Last week we joined the FSHD Society and members of the #FSHD community in Denver for the annual International Research Congress.   Our Head of Therapeutics Alexandra Collin de l'Hortet presented highlights of the IND-enabling data package for our lead candidate EPI-321, an epigenetic therapy for the treatment of FSHD, including updated efficacy and safety data.   Thank you to all those who attended and continue to support our mission to develop a new therapeutic approach for people living with FSHD.   #IRC2024 #CureFSHD

We are on the ground at FSHD Society #IRC2024 and looking forward to sharing the latest on our lead program, EPI-321.    We are honored to partner with organizations like the FSHD Society as we work to #CureFSHD by addressing its epigenetic root cause.

Next week we will be at the FSHD Society International Research Congress, where our Head of Therapeutics Alexandra Collin de l'Hortet will present highlights of the IND-enabling data package for EPI-321, our lead program targeting #FSHD.   See the full details in today’s release: https://lnkd.in/eVeHgefM #IRC2024 #CureFSHD